# Evrysdi™ (risdiplam) Solution and Tablets
## (Oral)

**Effective Date: 01/01/2021**
**Reviewed Date: 10/2020, 6/2021, 04/2022, 03/2023, 03/2024, 02/2025, 04/2025, 03/2026**
**Scope: Medicaid**

## I. Indication

Evrysdi is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. All other indications are considered experimental/investigational and not medically necessary.

## II. Length of Authorization

Coverage will be provided every 6 months and may be renewed.

## III. Initial Approval Criteria[1-6]

**Universal Criteria**

- Member must not have previously received treatment with SMA gene therapy (i.e., onasemnogene abeparvovec-xioi, onasemnogene abeparvovec-brve); **AND**
- Member will not use in combination with other agents for SMA (e.g., onasemnogene abeparvovec, nusinersen, etc.); **AND**
- Member must not have advanced disease (e.g., complete limb paralysis, permanent ventilation support or have a tracheostomy, etc.); **AND**
- Documentation of the member's current weight and age are provided; **AND**
- Dose does not exceed FDA approved labeling for the member's weight and age**; AND**

**Spinal Muscular Atrophy (SMA) † Φ [1-6]**

- Member retains meaningful voluntary motor function (e.g. manipulate objects using upper extremities, ambulate, etc.); **AND**
- Member must have a diagnosis of 5q spinal muscular atrophy confirmed by either homozygous deletion of the *SMN1* gene or dysfunctional mutation of the *SMN1* gene; **AND**
- Member must have a documented diagnosis of SMA phenotype I, II, or III; AND
    - Member has ≤ 3 copies of the *SMN2* gene; OR
    - Member has symptomatic disease (i.e., impaired motor function and/or delayed motor milestones); AND
- Baseline documentation of one or more of the following:

- Motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Bayley Scales of Infant and Toddler development Third Ed. (BSID-III), 6-minute walk test (6MWT), upper limb module (ULM), motor function measure 32 (MFM32), revised upper limb module (RULM), etc.
- Respiratory function tests [e.g., forced vital capacity (FVC), etc.]
- Exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
- Member weight (for members without a gastrostomy tube)

† FDA-labeled indication(s), ‡ Compendia recommended indication(s); **Φ** Orphan Drug

## IV. Renewal Criteria[1-6]

- Member continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), etc. identified in section III; **AND**
- Member will not use in combination with other agents for SMA (e.g., onasemnogene abeparvovec, nusinersen, etc.); **AND**
- Absence of unacceptable toxicity, which would preclude safe administration of the drug. Examples of unacceptable toxicity include the following: severe diarrhea, etc.; **AND**
- Member has responded to therapy compared to pretreatment baseline in one or more of the following:
  - Stability or improvement in net motor function/milestones, including but not limited to, the following validated scales: Hammersmith Infant Neurologic Exam (HINE), Hammersmith Functional Motor Scale Expanded (HFMSE), Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND), Bayley Scales of Infant and Toddler development Third Ed. (BSID-III), 6-minute walk test (6MWT), upper limb module (ULM), motor function measure 32 (MFM32), revised upper limb module (RULM), etc.
  - Stability or improvement in respiratory function tests [e.g., forced vital capacity (FVC), etc.]
  - Reduction in exacerbations necessitating hospitalization and/or antibiotic therapy for respiratory infection in the preceding year/timeframe
  - Stable or increased member weight (for members without a gastrostomy tube)
  - Slowed rate of decline in the aforementioned measures

## V. Dosage/Administration and Quantity Limits

| Indication | Dose |
|---|---|
| Spinal Muscular Atrophy | Evrysdi is administered orally once daily. The recommended dosage is determined by age and body weight, as follows:<br>• Less than 2 months of age: 0.15mg/kg |

| | |
|---|---|
| | • 2 months to < 2 years of age: 0.2 mg/kg<br>• 2 years of age and older weighing < 20 kg: 0.25 mg/kg<br>• 2 years of age and older weighing ≥ 20 kg: 5 mg |
| Store the constituted oral solution of Evrysdi in the original amber bottle to protect from light.<br>Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Discard any unused portion after 64 days. | |

- Quantity Limit
  - 5mg per day
  - Evrysdi 60 mg oral solution: 2 bottles every 24 days (6.67 mL per day)
  - Evrysdi 5 mg tablet: 1 tablet daily

## VI. Billing Code/Availability Information

NDC:
Evrysdi 0.75 mg/mL oral solution – 60 mg glass bottle: 50242-0175-xx
Evrysdi 5 mg tablet- 30 count bottle: 50242-0202-xx

## VII. References

1. Evrysdi [package insert]. South San Francisco, CA; Genentech, Inc.; October2023. Accessed April 2025.
2. Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007 Aug;22(8):1027-49.
3. Prior TW, Finanger E. Spinal muscular atrophy. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1352/ (Accessed on August 13, 2020).
4. Kichula E, Duong T, Glanzman A, et al. Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) Feasibility for Individuals with Severe Spinal Muscular Atrophy II (S46.004). Neurology Apr 2018, 90 (15 Supplement) S46.004
5. Hoffman-La Roche. Investigate Safety, Tolerability, PK, PD and Efficacy of Risdiplam (RO7034067) in Infants With Type1 Spinal Muscular Atrophy (FIREFISH). Available from: https://clinicaltrials.gov/ct2/show/NCT02913482?term=NCT02913482&draw=2&rank=1. NLM identifier: NCT02913482. Accessed August 13, 2020.
6. Hoffman-La Roche. A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants (SUNFISH). Available from: https://clinicaltrials.gov/ct2/show/NCT02908685?term=NCT02908685&draw=2&rank=1. NLM identifier: NCT02908685. Accessed August 13, 2020.

## Appendix 1 – Covered Diagnosis Codes

| ICD-10 | ICD-10 Description |
|---|---|
| G12.0 | Infantile spinal muscular atrophy, type I [Werdnig-Hoffmann] |
| G12.1 | Other inherited spinal muscular atrophy |

| ICD-10 | ICD-10 Description |
|---|---|
| G12.25 | Progressive spinal muscle atrophy |
| G12.8 | Other spinal muscular atrophies and related syndromes |
| G12.9 | Spinal muscular atrophy, unspecified |